AbbVie asks US Supreme Court to weigh protections for attorney records
By Mike Scarcella
July 11 (Reuters) -Pharmaceutical company AbbVie ABBV.N has asked the U.S. Supreme Court to take up its fight to protect corporate records, warning that a lower court ruling threatens to erode the shield that keeps most attorney communications off-limits from a company's courtroom opponents.
The Illinois-based drugmaker petitioned the justices this week to review a U.S. appeals court decision that said the filing of a sham patent-infringement lawsuit can overcome attorney-client privilege.
AbbVie is battling allegations in Philadelphia federal court from a group of drug wholesalers that claim they were overcharged for the blockbuster testosterone replacement drug AndroGel.
Purchasers including AmerisourceBergen and McKesson said AbbVie pursued a meritless patent case against drugmaker Perrigo PRGO.N in 2011 to delay its marketing of cheaper generic version of AndroGel.
The 3rd U.S. Circuit Court of Appeals in February ruled that AbbVie must turn over to the wholesalers 19 documents that include in-house attorney notes and memos from outside attorneys addressing the company’s lawsuit against Perrigo.
The appeals court said sham patent cases can be considered fraudulent activity that triggers what is known as the crime-fraud exception, which pierces the attorney-client privilege if a client's communication with an attorney was made with the intention to further a crime.
AbbVie told the justices that the ruling greatly expanded the crime-fraud exception. It said the 3rd Circuit and the Washington, D.C.-based Federal Circuit, which specializes in litigation over intellectual property, are in conflict over what “fraud” triggers the exception.
The 3rd Circuit’s decision will incentivize plaintiffs to file antitrust lawsuits claiming that related patent litigation was a sham, AbbVie told the Supreme Court. Those plaintiffs would be able weaponize the threat that they will get their hands on internal attorney records.
AbbVie and attorneys for the wholesalers did not immediately respond to requests for comment on Wednesday. AbbVie denies wrongdoing. The company, which was spun off by Abbott Laboratories in 2012, has said it had a valid basis to sue Perrigo.
AndroGel’s annual U.S. net sales sometimes topped $1 billion before 2015, when generic versions entered the market.
Litigation over AndroGel has dragged out for years, and included a Federal Trade Commission lawsuit that has since been resolved. The drug wholesalers’ case against AbbVie was filed in 2019.
The case is In re: Abbott Laboratories et al, U.S. Supreme Court, unassigned.
For petitioners: Donald Verrilli of Munger, Tolles & Olson
For respondents: No appearance yet
Read more:
Here’s what AbbVie doesn’t want you to know about its sham AndroGel patent case
Perrigo loses bid to revive antitrust case against AbbVie over AndroGel
U.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel drug
U.S. court voids $448 million award against AbbVie, but revives FTC claim over AndroGel
Reporting by Mike Scarcella
免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。